NCT06840821 2025-12-02
Evaluating the Safety, Tolerability, and Preliminary Anti-tumor Activity of MB0151 in Adult Subjects With Advanced Solid Tumors Expressing Somatostatin Receptors
Mainline Biosciences (Shanghai) Co., Ltd
Phase 1/2 Recruiting
Mainline Biosciences (Shanghai) Co., Ltd
Vibrant Sciences Limited
Bio-Thera Solutions
Risen (Suzhou) Pharma Tech Co., Ltd.